Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hellmann

Showing results (141-150 of 235) with videos related to

Pageof 24
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
JCO Precision Oncology|June 14, 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung CancersMichael Offin, Robin Guo, Stephanie L Wu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2022
Deciphering radiological stable disease to immune checkpoint inhibitorsJ Luo, S Wu, H Rizvi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like SubsetsNatasha Rekhtman, Maria C Pietanza, Matthew D Hellmann, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2013
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabMatthew D Hellmann, Jamie E Chaft, Valerie Rusch, et al.
The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2016
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerM Chatterjee, D C Turner, E Felip, et al.
Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.
Pageof 24

Showing results (141-150 of 235) with videos related to

Sort By:
Pageof 24
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
JCO Precision Oncology|June 14, 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung CancersMichael Offin, Robin Guo, Stephanie L Wu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2022
Deciphering radiological stable disease to immune checkpoint inhibitorsJ Luo, S Wu, H Rizvi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like SubsetsNatasha Rekhtman, Maria C Pietanza, Matthew D Hellmann, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2013
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabMatthew D Hellmann, Jamie E Chaft, Valerie Rusch, et al.
The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2016
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerM Chatterjee, D C Turner, E Felip, et al.
Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.
Pageof 24